Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03083808
Title Phase II Trial of Continuation Therapy in Advanced NSCLC
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Greg Durm
Indications

lung non-small cell carcinoma

Therapies

Gemcitabine + Pembrolizumab

Docetaxel + Pembrolizumab

Pembrolizumab + Pemetrexed Disodium

Pemetrexed Disodium

Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Illinois Cancer Center Chicago Illinois 60612 United States Details
Indiana University Melvin and Bren Simon Cancer Center Indianapolis Indiana 46202 United States Details
University of Iowa Hospital Clinics Iowa City Iowa 52242 United States Details
University of Minnesota Medcical Center Minneapolis Minnesota 55455 United States Details
University of Wisconsin Madison Wisconsin 53705 United States Details
*Shaded cells indicate that there was no data available from clincialtrials.gov for the field